CONCLUSIONS The PROMUS Element stent demonstrated very low TLF and revascularization rates with favorable safety outcomes for the treatment of small vessels and long lesions through 5 years.
BACKGROUND Recent study reported that arterial healing of drug eluting stents was impaired with greater delay at the flow divider (high shear stress region) as compared with the opposite side of side branch (SB) (low shear stress region). This study investigated the differences in neointimal growth on stent struts between thin-and thick-strut drug eluting stents (DES) implanted in coronary bifurcation lesions by using optical coherence tomography (OCT).
METHODS Sixty-two bifurcation lesions treated with second generation DES were evaluated with OCT in 51 patients (66.1 y.o) at 6 to 12 months follow-up angiography. The stent strut was defined as thin when less than 100mm and thick when more than 100mm. Each lesions were divided into thick-DES (n¼20; Nobori biolimus-eluting stents) or thin-DES (n¼42; Xience everolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents). Neointimal coverage was assessed based on cross-sectional OCT images containing SB at 400mm interval, and separately evaluated according to three independent regions: SB ostium (SO), the 1/2 circumference of the vessel wall opposite to SB (LS; low share stress region), and the vessel wall adjacent to SB (HS; high shear stress region). Incidence of uncovered struts and neointimal thickness were measured on the cross sectional OCT images.
RESULTS Total of 2437 struts were analyzed in this study (thick-DES: 911 vs. thin-DES: 1526). The incidence of uncovered struts was significantly higher at HS region compared with LS regions in thick-DES (16.8% vs. 7.9%, p<0.01), while there was no significant difference in thin-DES at both HS and LS region (7.3% vs. 5.4%, p¼0.1643). The incidence of uncovered struts was significantly higher in thick-DES compared with thin-DES at HS region (16.8% vs 7.3%, p<0.01), while there was no significant difference at both LS and SO region (7.9% vs. 5.4%, p¼0.0846; 34.7% vs. 36.4%, p¼0.7606, respectively). Neointimal thickness was significantly smaller in thick-DES compared with thin-DES at both HS and LS region (69.4AE46.6mm vs. 99.9AE70.8mm, p<0.01; 72.2AE47.6mm vs. 98.5AE69.5mm, p<0.01, respectively), while there was no significant difference at SO region (48.7AE31.8mm vs. 48.7AE36.1mm, p¼0.8386).
CONCLUSIONS Thin strut DES was homogeneously endothelialized in bifurcation lesions and may have more favorable arterial healing response for bifurcation lesions compared with thick strut DES.
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Results after recanalization of true coronary chronic total occlusions with the sirolimus eluting abluminal coated stent compared with the zotarolimus eluting stent Julia Seeger, 1 Sinisa Marcovic, 1 Birgid Gonska, 1 Wolfgang Rottbauer, 1 Jochen Wöhrle 1 1 University of Ulm, Ulm, Germany BACKGROUND Chronic total occlusions (CTO), defined by TIMI 0 flow and duration of occlusion of more than 3 month, are associated with a higher risk of restenosis compared to other lesion types. We evaluated clinical and angiographic results after recanalization of CTOs with the Sirolimus eluting Orsiro hybrid stent with bioresorbable polymer coating. Orsiro is a cobalt chromium stent with an absorbable polymer and thin struts of 60 mm. We compared two consecutive patient series undergoing recanalization for CTO with either the Orsiro Sirolimuseluting stent (O-SES) or a Zotarolimus-eluting stent (ZES)
METHODS 74 patients after successful recanalization of a true CTO in a native coronary artery where enrolled in our prospective registry (clinical trials.gov NCT02162082) and compared with 57 patients treated with a Zotarolimus-eluting stent. In 68 % vs 50% CTO recanalization was performed by antegrade and in 32%vs 5% by retrograde approach. After pre-dilatation a mean of 2.7AE1.3 (range 1-6) Orsiro stents and 2.7AE1.2 (1-7) ZES were implanted with a mean length of 81.9AE30.6mm. 32.4% (N¼ 24/74) of patients in the Orsiro group suffered from diabetes mellitus and 28.1%(N¼16/57)in the Zotarolimus group. In 66.2% vs 61.4% CTO was located in RCA, 18.9%vs15.8% in LCX and in 14.9%vs 22.8% in LAD. Reference diameter post PCI was 3.04AE0.49mm (3.19AE0.56mm), MLD 2.82AE0.51mm (3.06AE0.48mm) and percent diameter stenosis 7.6AE10.0 (3.7AE8.3). Dual antiplatelet therapy (DAPT) was recommended for 12 months with aspirin and clopidogrel. Control angiography was scheduled after 9 and clinical follow-up after 12 month. The primary angiographic outcome was instent late lumen loss. Secondary angiographic endpoints include minimal luminal diameter, percentage of diameter stenosis, binary restenosis. Primary clinical outcome measures were target lesion revascularization rate (TLR) and major adverse cardiac events (MACE) defined as composite of cardiac death, myocardial infarction related to the target vessel and target vessel revascularization.
RESULTS
The primary endpoint in-stent late lumen loss was 0.24AE0.53mm for the Orsiro stent compared with 0.59AE0.72mm for the Zotarolimus stent (p¼0.01), MLD was 1.99AE0.63mm versus 1.87AE0.80mm (p¼0.86), percent diameter stenosis 24.7AE19.2% vs. 27.7AE28.7% (p¼0.58), respectively. TLR was 9.7% for O-SES and 10.5 % for ZES, resulting in a total MACE rate of 10.8% vs 12.3% (p¼0.79). Of note, there was no definite or probable stent thrombosis according to ARC criteria in both groups within 12 months DAPT treatment.
CONCLUSIONS Treatment of true CTO lesions with the Sirolimus eluting abluminal coated Orsiro stent resulted in a significantly lower in-stent late lumen loss compared with Zotarolimus eluting stents and no occurrence of definite or probable stent thrombosis with a 12 months dual antiplatelet therapy. Clinical results were similar to Zotarolimus eluting stents. 
